GSK announced results from its PRIMA Phase III trial, in which niraparib was studied as a maintenance therapy in women with first-line ovarian cancer following a response to platinum-based chemotherapy. The data showed that the drug resulted in a 38% reduction in the risk of disease progression or death in the overall population, driven by
Pfizer and Astellas have announced results from the Phase III ARCHES trial in men with metastatic hormone-sensitive prostate cancer (HSPC), showing that Enzalutamide had significantly improved radiographic progression-free survival, paving the way for an application to expand the drug’s use. The results, which are for the drug in combination with androgen deprivation therapy, show a
The Clinical Professionals Group are delighted to announce we have raised over £130 for Bloodwise! Bloodwise, originally known as Leukaemia and Lymphoma Research, is one of the UK’s leading charities for blood cancer research. The charity was first set up in 1960 by the Eastwood family, who upon losing their 6-year-old daughter to leukaemia, set
After a period of speculation Pfizer has recently stepped forward with a $14-billion bid for Medivation, trouncing Sanofi and other suitors in a move designed to boost its oncology portfolio. Pfizer announced a definitive merger agreement under which it will acquire the US biopharma (which is currently focused on developing and commercialising small molecules for
Celgene and Jounce Therapeutics are to join in a global strategic collaboration with the aim of developing and commercialising immuno-oncology treatments. The collaboration will provide Celgene the options to jointly develop and commercialise Jounce’s primary product candidate, JTX-2011, and other innovative immunotherapies targeting B cells, T regulatory cells and tumor-associated macrophages.
Cancer Research UK’s Centre for Drug Development (CDD), in partnership with Amgen, have launched a new clinical trial to test a drug with the aim to stop a patient’s immune system from protecting tumours.
A report has stated that a nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumours whilst decreasing toxicity. In their report that has received advance online publication in Nature Nanotechnology, a research team based at the Wellman Center for Photomedicine